Graves disease
Drug research and approvals for graves disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 65 studies of graves disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 65
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye DiseaseNCT07885605 · Phase 1 · Ethyreal Bio, Inc. · starts Jul 6, 2026
- Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye DiseaseNCT07835607 · Not reported · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · starts Nov 14, 2025
- An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabNCT07832136 · Phase 4 · Viridian Therapeutics, Inc. · starts Oct 19, 2026
- Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' DiseaseNCT07812194 · Not reported · University of Copenhagen · starts Oct 16, 2026
- Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)NCT07753603 · Phase 3 · Sling Therapeutics, Inc. · starts Aug 4, 2026
- A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease…NCT07722546 · Phase 2 · Biogen · starts Jul 30, 2026
- Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE…NCT07716397 · Not reported · Shanghai Changzheng Hospital · starts Jan 1, 2026
- Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' DiseaseNCT07682896 · Phase 2 · Yarrow Bioscience, Inc. · starts Jun 10, 2026
- Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' DiseaseNCT07661056 · Phase 3 · Biohaven Therapeutics Ltd. · starts Jun 26, 2026
Phase 3 2
- PropylthiouracilThyroid peroxidase inhibitor
- CholestyramineBile acids sequestering agent
Phase 2 6
- MethimazoleThyroid peroxidase inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- LevothyroxineThyroid hormone receptor agonist
- Thyrotropin alfaThyroid stimulating hormone receptor agonist
- IscalimabTumor necrosis factor receptor superfamily member 5 inhibitor
- BatoclimabIgG receptor FcRn large subunit p51 inhibitor
Phase 1 or earlier 2
- RituximabB-lymphocyte antigen CD20 binding agent
- DexamethasoneGlucocorticoid receptor agonist
How its trials ended
110 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 50% met their primary endpoint, 21% missed it and 29% stopped early.
- Completed, result not reported5348%
- Ongoing2624%
- Status unknown1715%
- Met its primary endpoint76%
- Missed its primary endpoint33%
- Stopped: enrollment or feasibility33%
- Stopped: other or unclear11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA